Literature DB >> 33329930

Quantitative parameters of MRI and 18F-FDG PET/CT in the prediction of breast cancer prognosis and molecular type: an original study.

Pavel Borisovich Gelezhe1,2, Ivan Andreevich Blokhin1, Damir Ildarovich Marapov3, Sergey Pavlovich Morozov1.   

Abstract

The purpose of this work is to evaluate the quantitative parameters of magnetic resonance imaging (MRI), particularly diffusion-weighted imaging (DWI) and dynamic contrast enhancement (DCE) as well as positron-emission tomography, combined with computer tomography (PET/CT), with 18F-fluorodesoxyglucose, in the prediction of breast cancer molecular type. We studied the correlation between a set of parameters in the invasive ductal carcinoma of the breast, not otherwise specified (IDC-NOS) as it is the most common invasive breast tumor. The parameters were as follows: apparent diffusion coefficient (ADC) in DWI, positive enhancement integral (PEI) in DCE, maximum standardized uptake value (SUVmax) in 18F-FDG PET/CT, tumor size, grade, and Ki-67 index, level of lymph node metastatic lesions. We also evaluated the probability of a statistically significant difference in mean ADC, PEI, and SUVmax values for patient groups with different Nottingham prognostic index (NPI) and molecular tumor type. Statistically significant correlations between SUVmax, tumor size, and NPI, mean and minimal ADC values with Ki-67 and molecular tumor type were found. The PEI showed a correlation with the NPI risk level and was characterized by a relationship with the magnitude of the predicted NPI risk and regional lymph node involvement. The prognostic model created in our work allows for NPI risk group prediction. The SUVmax, ADC and PEI are non-invasive prognostic markers in the invasive breast cancer of no specific type. The correlation between ADC values and the expression of some tumor receptors can be used for in vivo molecular tumor type monitoring and treatment adjustment. AJNMMI
Copyright © 2020.

Entities:  

Keywords:  18F-FDG PET/CT; Breast cancer; DCE; DWI; breast MRI

Year:  2020        PMID: 33329930      PMCID: PMC7724282     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  28 in total

1.  In vivo diffusion-weighted MRI of the breast: potential for lesion characterization.

Authors:  Shantanu Sinha; Flora Anne Lucas-Quesada; Usha Sinha; Nanette DeBruhl; Lawrence W Bassett
Journal:  J Magn Reson Imaging       Date:  2002-06       Impact factor: 4.813

2.  Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression.

Authors:  Yoshihisa Umekita; Masakazu Souda; Yasuyo Ohi; Yoshiatsu Sagara; Yoshiaki Rai; Tetsuya Takahama; Hiroki Yoshida
Journal:  Pathol Int       Date:  2006-08       Impact factor: 2.534

3.  Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers.

Authors:  Hye Ryoung Koo; Nariya Cho; In Chan Song; Hyeonjin Kim; Jung Min Chang; Ann Yi; Bo La Yun; Woo Kyung Moon
Journal:  J Magn Reson Imaging       Date:  2012-03-05       Impact factor: 4.813

4.  Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.

Authors:  Kazuhiro Kitajima; Kazuhito Fukushima; Yasuo Miyoshi; Arisa Nishimukai; Seiichi Hirota; Yoko Igarashi; Takayuki Katsuura; Kaoru Maruyama; Shozo Hirota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-07       Impact factor: 9.236

5.  FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion.

Authors:  Masatoyo Nakajo; Yoriko Kajiya; Tomoyo Kaneko; Youichi Kaneko; Takashi Takasaki; Atsushi Tani; Masako Ueno; Chihaya Koriyama; Masayuki Nakajo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-07       Impact factor: 9.236

6.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.

Authors:  Ji Hyun Youk; Eun Ju Son; Jin Chung; Jeong-Ah Kim; Eun-Kyung Kim
Journal:  Eur Radiol       Date:  2012-04-17       Impact factor: 5.315

7.  Influence of post-treatment delay on the evaluation of the response to focused ultrasound surgery of breast cancer by dynamic contrast enhanced MRI.

Authors:  A Khiat; D Gianfelice; M Amara; Y Boulanger
Journal:  Br J Radiol       Date:  2006-04       Impact factor: 3.039

8.  18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.

Authors:  Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Nariya Cho; Jung Min Chang; Min Sun Bae; Won Hwa Kim; Su Hyun Lee; Mi Young Kim; Jin You Kim; Mirinae Seo; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

9.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

Review 10.  Basal-like breast cancer: a critical review.

Authors:  Emad A Rakha; Jorge S Reis-Filho; Ian O Ellis
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

View more
  2 in total

1.  ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer.

Authors:  Weiyu Chen; Miao Li; Muhsin H Younis; Todd E Barnhart; Dawei Jiang; Tuanwei Sun; Joshua M Lang; Jonathan W Engle; Min Zhou; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09-14       Impact factor: 9.236

2.  Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding.

Authors:  Lale Umutlu; Julian Kirchner; Nils Martin Bruckmann; Janna Morawitz; Gerald Antoch; Marc Ingenwerth; Ann-Kathrin Bittner; Oliver Hoffmann; Johannes Haubold; Johannes Grueneisen; Harald H Quick; Christoph Rischpler; Ken Herrmann; Peter Gibbs; Katja Pinker-Domenig
Journal:  Cancers (Basel)       Date:  2021-06-11       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.